

Pocket Guidelines

Management
of Patients with
**Gynecological
Cancers During
Pregnancy**



Pocket Guidelines

Based on ESGO-INCIP
guidelines for the management
of patients with gynecological
cancers during pregnancy

Amant, F., Planchamp, F., ... Halaska, M.J. (2025). ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy. *International Journal of Gynecological Cancer*. Sep;35(9):101975. doi: 10.1016/j.ijgc.2025.101975

Gynecological cancers during pregnancy are rare, affecting around 2 to 5 per 100,000 pregnancies primarily during the first trimester. Managing these cancers remains a challenge for patients, their physicians, and health care systems. Both maternal and fetal health should be considered, and specialized management strategies should be implemented to improve patient outcomes. Optimal management should aim to improve the benefit of treatment for the mother while minimizing harm to the fetus, considering the extent of the disease, treatment options, and gestational age at which treatment is considered with the ultimate goal of achieving a prognosis similar to that of non-pregnant patients.

Over the last decade, the European Society of Gynecological Oncology (ESGO) organized 3 international consensus meetings with leading experts in the field to define protocols and to provide guidance for pregnant patients and healthcare providers on the management of gynecological cancers in pregnancy. Following the third consensus meeting, a collaboration was established between the ESGO and the International Network on Cancer, Infertility and Pregnancy (INCIP) with the specific objective of updating the guidelines by incorporating new evidence on this field and covering new topics to provide comprehensive evidence-based guidelines on all relevant issues within a multidisciplinary setting.

Attention was given to imaging, pathology, surgery, medical oncology, obstetrics, radiation therapy, psychology, patient perspectives and pediatric follow-up within a multidisciplinary setting for patients with ovarian, cervical, and vulvar cancers during pregnancy.

The guidelines were developed using a five-step process as defined by the ESGO Guideline Committee:



The objectives of these ESGO/INCIP guidelines are to improve the quality of care for patients with gynecological cancers during pregnancy across Europe and worldwide. They are intended for use by all health professionals involved in the management of these patients across all allied disciplines.

These guidelines do not include any economic analysis of the strategies. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment.

To ensure that the statements were evidence based, the current literature was reviewed and critically appraised. A literature review of relevant studies published between January 2014 and June 2024 was carried out.

The guidelines were adopted if they were supported by sufficient high level of scientific evidence and/or when a large consensus among experts was obtained. An adapted version of the "Infectious Diseases Society of America-United States Public Health Service Grading System" was used to define the level of evidence and grade of recommendation for each of the recommendations:

LEVELS OF EVIDENCE

- I** Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted, randomised trials without heterogeneity
- II** Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity
- III** Prospective cohort studies
- IV** Retrospective cohort studies or case-control studies
- V** Studies without control group, case reports, expert opinions

GRADES OF RECOMMENDATIONS

- A** Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
- B** Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
- C** Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional
- D** Moderate evidence against efficacy or for adverse outcome, generally not recommended
- E** Strong evidence against efficacy or for adverse outcome, never recommended

ESGO would like to thank the members of the international development group for their constant availability, work, and for making possible the development of these guidelines for the management of patients with gynecological cancers during pregnancy (see below). ESGO is also very grateful to the 103 international external reviewers (clinicians and patient representatives) for their participation (list available on the ESGO website).

Name Specialty

Affiliation

Frédéric Amant

Gynecologic oncologist (chair)

Michael J. Halaska

Gynecologic oncologist (chair)

François Planchamp

Methodologist

Paul Berveiller

Obstetrician

Elyce Cardonick

Perinatologist

Anne De Middelaer

Patient representative

Robert Fruscio

Gynaecological Oncologist

Monica Fumagalli

Neonatologist

Anna L.V. Johansson

Epidemiologist

Matteo Lambertini

Medical Oncologist

Charlotte L. LeJeune

Obstetrician

Christianne Lok

Gynaecological Oncologist

W. Glenn McCluggage

Pathologist

Philip Poortmans

Radiation Oncologist

Jacek Sienko

Gynaecological Oncologist

Cristel S. Hjortshøj

Pediatrician

Marta Swierczynska

Psychologist

Antonia Carla Testa

Gynecologist/sonographer

Indra A. Van Assche

Psychologist

Kristel Van Calsteren

Perinatologist

Vincent Vandecaveye

Radiologist

Carolien Versteeg

Patient representative

Flora Zagouri

Medical Oncologist

Ignacio Zapardiel

Gynaecological Oncologist

KU Leuven, Leuven (Belgium)

Netherlands Cancer Institute, Amsterdam (The Netherlands)

Charles University, 3rd Medical Faculty, Prague (Czech Republic)

University Hospital Kralovske Vinohrady, Prague (Czech Republic)

Institut Bergonié, Bordeaux (France)

Poissy-Saint Germain Hospital, Poissy (France)

Paris Saclay University, Montigny-Le-Bretonneux (France)

Cooper University Health Care, Camden, NJ (USA)

ESGO - ENGAGE, Brussels (Belgium)

University of Milan-Bicocca, Milano (Italy)

Fondazione IRCCS San Gerardo dei Tintori, UO Gynecology, Monza (Italy)

University of Milan, Milan (Italy)

Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan (Italy)

Karolinska Institutet, Stockholm (Sweden)

IRCCS Ospedale Policlinico San Martino, Clinica di Oncologia Medica, Genova (Italy)

University of Genova, School of Medicine, Genova (Italy)

KU Leuven, Leuven (Belgium)

Netherlands Cancer Institute, Amsterdam (The Netherlands)

Belfast Health and Social Care Trust, Belfast (UK)

Iridium Network, Wilrijk-Antwerp (Belgium)

University of Antwerp, Wilrijk-Antwerp (Belgium)

Medical University of Warsaw, Warsaw (Poland)

Copenhagen University Hospital, Copenhagen (Denmark)

Polish Lymphoma Association Owl Eyes, Warsaw (Poland)

Masovian Oncology Hospital in Warsaw, Warsaw (Poland)

Fondazione Policlinico Universitario A Gemelli IRCCS, Rome (Italy)

KU Leuven, Leuven (Belgium)

University Hospitals Leuven, Leuven (Belgium)

University Hospitals Leuven, Leuven (Belgium)

KU Leuven, Leuven (Belgium)

Stichting Olijf, Utrecht (Netherlands)

Alexandra Hospital, Athens (Greece)

La Paz University Hospital, Madrid (Spain)



Table of contents

General recommendations	8
Incidence and prognosis	9
Imaging	9
Pathology	10
Surgery	11
Anesthesia	11
Surgical procedures	11
Minimally invasive approach	12
Fetal monitoring	12
Analgesia	12
Medical oncology	13
Obstetrics	14
Thromboprophylaxis during and after pregnancy	14
Obstetric operative care	16
Pregnancy: evaluation, treatment and fetal follow-up	16
Delivery	17
Postpartum and newborn care	17
Radiation therapy	18
Psychology	20
Patient perspectives	20
Pediatric follow-up	21

General recommendations

- A** Staging and treatment should be discussed within a multidisciplinary team (generally at a tumor board meeting, composed according to local guidelines and complemented by perinatologist/neonatologist consultation). This discussion should be based on comprehensive and precise knowledge of prognostic and predictive factors for maternal and fetal outcomes, including morbidity, long-term side effects and quality of life.
- A** Patients and their partners should receive careful counseling about the suggested diagnostic and treatment plan and potential alternatives, including risks and benefits, long-term side effects of all options and the impact on quality of life.
- A** Work-up and treatment should be conducted in a specialized center or by a dedicated team of specialists in the diagnosis and management of gynecological cancers.
- B** Policy makers/medical societies are encouraged to establish such centers if they are not yet available.
- B** Pregnant women should receive oncologic treatment as close as possible to the standard care for non-pregnant patients to ensure optimal maternal outcomes.
- C** Depending on the gestational age at diagnosis, type of cancer and stage of the disease, optimal therapy and its timing may require individualized modifications during pregnancy.
- A** Research regarding the oncological, psychological, and obstetrical follow-up, as well as long-term outcomes of children prenatally exposed to cancer treatment, is strongly encouraged.
- C** The registration of all cancer cases during pregnancy is recommended, for example in the INCIP database (www.cancerinpregnancy.org) or national registries, to enable the monitoring of incidence, management strategies and maternal and fetal outcomes.

Incidence and prognosis

- B** As the incidence of cancer in pregnancy is not decreasing, clinicians should remain aware that cancer can complicate pregnancy, especially in unscreened populations and/or populations with higher maternal age.
- A** It is recommended to investigate pregnant patients presenting with symptoms that could be caused by cancer without delay, to obtain an early diagnosis. If cancer is confirmed, it is recommended to perform locoregional and distant staging as in non-pregnant patients whenever possible.
- A** Pregnancy itself does not worsen the prognosis of gynecological cancers, therefore pregnancy-preserving treatment should be considered.

Imaging

- A** Ultrasound examination is recommended for diagnosis and staging as it is a safe imaging technique during pregnancy.
- A** Ultrasound examination is the preferred method for assessing adnexal masses, preferably using a transvaginal approach.
- B** Magnetic resonance imaging (MRI) should be performed in patients with an adnexal mass with an inconclusive ultrasound examination.
- B** In case of a suspicious adnexal mass detected during the first trimester, referral of the patient to an experienced ultrasound examiner is recommended to avoid overtreatment.
- B** In case of an adnexal mass, ultrasound examination at 13-14 weeks' gestation is recommended to plan the appropriate management (surgery vs follow-up).
- B** In case of a suspicion of cervical cancer, transvaginal/transrectal ultrasound can be considered for staging in addition to MRI, but should only be performed by an expert.
- C** The response to neoadjuvant chemotherapy in patients with cervical cancer during pregnancy can be evaluated with transvaginal/transrectal ultrasound by an expert or by MRI.

- B** If indicated, whole body diffusion-weighted imaging/MRI or if unavailable, abdominal MRI with chest computed tomography (CT), is recommended as the primary imaging modality for staging pregnant patients with gynecological cancer. MRI should be used according to current clinical and safety guidelines for pregnancy.
- D** The use of gadolinium-based contrast agents during MRI examinations in pregnant women is not recommended as this can be obviated in most patients by the addition of a diffusion-weighted imaging sequence to the MRI examination.
- B** Iodinated contrast can be administered during a CT-examination when clinically relevant.
- D** The use of a lead apron for abdominal shielding during ionizing imaging is not recommended due to the risk of internal scatter leading to increased fetal exposure.
- C** In certain scenarios, low-dose positron emission tomography-CT might be considered when it might change the management.

Pathology

- A** The pregnant status and all other relevant clinical information should be recorded on the pathology request form by the clinician.
- B** Many of the gynecological tumors detected during pregnancy are uncommon and their morphological appearances may be modified by pregnancy; therefore, referral for a specialist pathology opinion should be considered.
- A** Certain rare non-neoplastic ("pseudoneoplastic") ovarian lesions occurring during pregnancy or postpartum may mimic neoplasms, especially sex cord-stromal tumors and, given the rarity of some of these and the possibility of misdiagnosis as malignant, referral for a specialist opinion should be considered.
- B** In the case of a gynecological malignancy discovered during pregnancy, the placenta should be submitted for pathological examination following delivery, including both gross and microscopic examination.

Surgery

Anesthesia

- B** Locoregional anesthesia is preferred over general anesthesia during pregnancy when feasible.
- B** If general anesthesia is required, surgery should not be postponed as it is safe in all trimesters.
- B** To avoid vena cava compression, a left lateral tilt (of at least 15 degrees) is recommended after 20 weeks gestation (16 weeks for twin pregnancies).

Surgical procedures

- B** If a surgical procedure cannot be postponed until after pregnancy, it should be performed during pregnancy, accepting a slightly increased risk of complications/miscarriage.
- B** Manipulation and trauma to the uterus should be avoided, especially during minimally invasive surgery.
- B** Small conization for suspected microscopic invasive cancer in pregnancy should be performed in the first or early second trimester.
- C** Simple trachelectomy/large cone for IB1 cervical cancer could be performed in pregnancy only in highly selected cases.
- D** Abdominal trachelectomy is not recommended during pregnancy.
- B** Lymph node staging should be performed if technically feasible as in non-pregnant patients.
- C** Given the lack of evidence, sentinel lymph node mapping using indocyanine should not be routinely performed but could be considered in cervical/vulvar cancer within a prospective clinical trial.
- B** A planned radical hysterectomy immediately following cesarean delivery is recommended as it will not lead to increased morbidity in experienced centers.

- B** For patients with operable cervical cancer and a non-pregnancy preserving intention, the following procedures are recommended after discussion with the patient:
 - First trimester: radical hysterectomy with the embryo in the uterus
 - Second trimester: radical hysterectomy after abdominal evacuation of the fetus
- B** Radical local excision for vulvar cancer in pregnancy should be performed without delay with the aim for free surgical margins.
- C** Pregnancy preserving staging surgery for ovarian cancer could be considered in the first or early second trimester.
- D** Cytoreductive surgery for advanced ovarian cancer is not recommended during pregnancy.

Minimally invasive approach

- B** Minimally invasive procedures are preferred over laparotomic procedures during pregnancy when indicated and feasible.
- B** Open introduction and if necessary adapted placement of trocars to avoid perforation of the uterus is recommended.
- B** Given the lack of evidence regarding the maximum safe duration of minimally invasive procedures in pregnancy and the known physiological consequences of high intra-abdominal pressure, procedures should be limited in both time and pressure.

Fetal monitoring

- B** It is recommended to monitor the fetus preoperatively and postoperatively.
- C** Fetal monitoring intraoperatively can be considered if active management of the newborn is the aim in case of fetal distress.

Analgesia

- A** Pregnant patients should be treated with adequate analgesia postoperatively, particularly to avoid preterm contractions.
- B** Best available options include:
 - Continuous epidural analgesia.
 - Acetaminophen (preferred throughout all stages of pregnancy).
 - Opioids (throughout all stages of pregnancy).

Medical oncology

- A** Before each cycle of chemotherapy during pregnancy, assessment by an obstetrician should be performed to assess maternal and fetal health, and the risk of premature labor.
- B** The choice of chemotherapy regimen when indicated should, like in non-pregnant patients, be based on cancer (sub)type and stage:
 - Ovarian epithelial cancer: paclitaxel/carboplatin every 3 weeks.
 - Ovarian non-epithelial cancer: bleomycin/etoposide/cisplatin or etoposide/cisplatin or paclitaxel/carboplatin every 3 weeks.
 - Cervical cancer: paclitaxel/carboplatin in weekly regimen or every 3 weeks.

Adaptations to standard treatment can be considered with regard to:

- B**
 - Expected fetotoxic effects:
 - All chemotherapeutic agents are expected to reach the fetal compartment to some extent depending on their pharmacokinetic characteristics.
 - Platinum-based chemotherapy, especially cisplatin, carries a risk for ototoxicity in the newborn, therefore carboplatin is preferred for gynecological malignancies except in germ cell cancers, where a cisplatin-based regimen is more effective.
- D**
 - Timing of chemotherapy:
 - Chemotherapy is not recommended before the 12th week of gestation.
 - Three-weekly chemotherapy should not be given after 35 weeks of gestation (to avoid hematopoietic suppression/neonatal chemotherapy toxicity).
 - Weekly chemotherapy should not be given after 36 weeks of gestation.
- A**
 - Chemotherapy dosing should be identical to non-pregnant women and based on actual maternal weight.
- B** If oncologists have concerns that a particular regimen or interval timing of chemotherapy during pregnancy may increase the risk of neutropenia, granulocyte colony-stimulating factors can be considered.
- B** Standard clinical investigations for assessment of the patient before and during systemic anticancer therapy must be performed for example:
 - Maternal echocardiogram in case of exposure to anthracyclines.
 - Pulmonary function testing in case of exposure to bleomycin.
 - Bone marrow function.

- B** Consider red blood cell transfusion when hemoglobin (Hb) is <8.0 g/dL (when Hb is <9.0 g/dL consider intravenous iron and erythropoietin).
- B** For the prevention of chemotherapy induced nausea, ondansetron and metoclopramide can be used.
- B** When corticosteroids are indicated, methylprednisolone and prednisolone should be used instead of dexamethasone.
- B** Port-a-cath placement should be preferred over peripherally inserted central catheters for chemotherapy administration because of increased risk of thrombosis.

Obstetrics

Thromboprophylaxis during and after pregnancy

- C** During pregnancy, it is advisable to use:
 - Compression stockings/intermittent pneumatic compression devices during surgery.
 - Prophylactic dose low-molecular-weight heparin (LMWH) at least 10 days after uncomplicated curative surgery during pregnancy.
 - Prophylactic dose LMWH as long as there is pelvic tumor load with an inflammatory reaction (like on chemotherapy), or compression on blood vessels, or an additional thrombosis risk factor (see Table 1).
- C** Cancer is an indication for postpartum LMWH prophylaxis for at least 10 days. With an additional risk factor (see Table 1) prophylactic use of LMWH till 6 weeks postpartum is advised.

Table 1 - Most common additional risk factors for thrombosis apart from gynecological cancer

Type	Description
High risk factors	• Dehydration (! Chemo-related nausea and vomiting) • Surgical procedure • Previous VTE • Medical co-morbidities (eg nephropathic syndrome, type 1 diabetes with nephropathy, heart failure, systemic inflammatory processes, cancer)
Risk factors	• Age > 35 y • Obesity (BMI≥30) • Parity ≥3 • ART/IVF • Smoking • Gross varicose veins • Immobility/hospitalization • Systemic infection • Thrombophilia (no VTE) • Blood transfusion
Obstetric risk factors	• Preeclampsia • Multiple pregnancy • C-section • Preterm birth • Prolonged labor (>24 h) • PPH > 1 L
Abbreviations: ART, assisted reproductive technology; BMI, body mass index; IVF, in vitro fertilization; PPH, primary postpartum hemorrhage; VTE, venous thromboembolism.	

Obstetric operative care

- A** If the ovary containing the corpus luteum gravidarum has been removed prior to 10-12 weeks of gestation, supplementation with exogenous progesterone should be initiated.
- C** When uterine manipulations are expected during surgery beyond the 22nd week of gestation, prophylactic use of tocolytic agents may be considered.

Pregnancy: evaluation, treatment and fetal follow-up

- A** After a cancer diagnosis early in pregnancy or an inadvertent pregnancy during cancer treatment, fetal ultrasound should be performed for accurate pregnancy dating.
- A** Treatment options, their impact on the pregnancy and the maternal prognosis should be discussed with the patient (depending on local legislation, including the option of termination of pregnancy).
- B** Non-invasive prenatal screening (NIPS) can be used; however, cell-free tumor DNA might interfere with the interpretation of NIPS.
- A** Before the onset of treatment, a fetal anatomy scan should be performed to identify fetal or placental abnormalities.
- B** Serial ultrasounds for fetal growth are recommended in patients undergoing cancer treatment, including surgery ± chemotherapy.
- B** After cervical surgery or right before each cycle of chemotherapy, assessment of cervical competence (or length) is advised, or signs of preterm labor should be investigated.
- B** Vaginal progesterone and cerclage should be used according to standard obstetric recommendations.
- B** Fetal anemia should be monitored using middle cerebral artery peak systolic velocity doppler when giving high-risk hematotoxic agents such as carboplatin, ifosfamide. In case of anemia (multiples of the median (MOM) >1.5) delay/stop of chemotherapy, reduction of dosage, change of chemotherapy regimen or even blood transfusion should be considered.

Delivery

- A** Iatrogenic preterm birth (<37 weeks) should be avoided as it is associated with greater odds of serious neonatal complications. The decision to induce a preterm delivery needs to be balanced with maternal treatment options and should be discussed within a multidisciplinary team including a neonatologist.
- B** Timing of delivery: If the patient is receiving chemotherapy, delivery ideally is timed at least 2 weeks following the last course of weekly chemotherapy and at least 3 weeks following the last course of a 3-weekly chemotherapy to avoid potential maternal infection/sepsis due to neutropenia, and potential fetal myelosuppression at the time of delivery.
- B** If cancer is diagnosed in the third trimester and only 1 cycle of chemotherapy is possible before delivery, patients should be counselled on the fetal risks of late preterm birth versus the maternal/fetal impact of a single cycle of chemotherapy during pregnancy.
- A** If preterm delivery is expected, corticosteroids for fetal lung maturation and magnesium sulfate for neuroprotection should be considered in accordance with standard obstetric recommendations.

Mode of delivery:

- B**
 - Cesarean delivery is recommended in cases of:
 - Vulvo-vaginal cancer after major surgery or with cancer still present/in situ.
 - Invasive cervical cancer, in which case it is important to avoid a lower uterine surgical incision or laceration toward the tumor. A corporeal/classical incision is preferred, especially for large tumors.
- C**
 - A vaginal delivery can be considered in cases of:
 - Previous complete removal of cervical cancer by conization.
 - Small completely removed vulvar cancer.
 - Tubo-ovarian malignant neoplasm.

Postpartum and newborn care

- A** The child exposed to cancer treatment *in utero* needs to be examined thoroughly by a neonatologist.

- A** Newborns exposed to chemotherapy *in utero* must be screened for transient neonatal myelosuppression, especially in cases of a short interval between the last course of chemotherapy and birth.
- B** If cardiotoxic treatment was administered during pregnancy, an echocardiogram can be considered.
- A** After platinum exposure, hearing function should be screened at birth with auditory brainstem response testing.
- A** Breastfeeding should be avoided when systemic anticancer therapy is required postpartum.
- C** Systemic anticancer therapy can be (re)started within the first days after uncomplicated vaginal delivery and after 1 week following caesarean delivery.
- A** A discussion regarding contraception is recommended at the postpartum visit for fertile patients requiring ongoing cancer treatment.
- A** Before considering a subsequent pregnancy, an oncologic assessment to exclude recurrence or treatment related toxicities are recommended.

Radiation therapy

- A** Radiation-related fetal risks based on calculation of estimated fetal radiation dose by a medical/clinical physicist should be included in the benefit-risk assessment of radiation therapy during pregnancy.
- B** When preservation of the pregnancy is the aim, pelvic and groin radiation therapy is contraindicated.
- B** Depending on the indication, gestational age and tumor type, a limited delay of radiation therapy should be considered if it allows for standard treatment (see Table 2 (indications per tumor type)).
- B** In case of advanced cervical cancer and a non-pregnancy preserving intention, the following options should be discussed with the patient depending on local legislation:
 - First trimester: radiation therapy without evacuation ± feticide
 - Second trimester: radiation therapy after abdominal evacuation or radiation therapy with fetus in the uterus with or without feticide
- B** For metastatic disease, radiation therapy using techniques that minimize fetal exposure could be considered for palliation.

Table 2 - Time to radiation therapy based on indication and tumor type

Tumor type/indication during pregnancy	Recommendations regarding radiation therapy	Impact of delay (eg, due to pregnancy)
General gynecological cancers	Preferred to delay radiation until after delivery; if not possible, limited local surgery or systemic therapy considered to postpone RT	Postponement risks progression; pregnancy termination may be advised if treatment cannot be delayed
Vulvar Cancer (node-positive SCC)	Initiate as soon as possible after surgery; optimal overall treatment time including surgery and RT ~ 104 days	Increased risk of death by 0.4% per additional day delay; postoperative RT should be completed within 105 days post-surgery
Cervical cancer – Primary CTRT	Mean time from diagnosis to (CT)RT ~ 7.7 weeks; waiting up to 12 weeks does not negatively impact survival	Delay up to 12 weeks may be acceptable without survival impact; OTT should ideally be <56 days (EMBRACE)
Cervical cancer – Postoperative RT	Induction chemotherapy (6x weekly carboplatin + paclitaxel) can be administered before definitive (CT)RT.	Based on INTERLACE trial, induction chemotherapy shows 9% and 8% improvement in 5-y progression-free survival and overall survival, so the use of induction chemotherapy can give 7 weeks of delay and for aiming a reduction of prematurity.
Proton RT	Should begin promptly after surgery Increasingly used based on tumor- and patient-specific factors as over 10-fold reduction in fetal exposure compared with photon-based RT can be obtained (pencil beam scanning-technique)	Delays associated with increased mortality risk; ESGO/ESTRO recommends "time diagnosis to RT <6w" and "OTT <50d" as quality indicators.
Palliative RT (pain, bleeding, metastases)	Generally, a single dose of 8 Gy standard; brain metastases may require 20 Gy in 5 fractions	In pregnancy, lower prescribed dose should be considered to reduce fetal exposure (eg, down to 4 Gy for bone metastases)
Abbreviations: CTRT, chemoradiation therapy; ESGO, European Society of Gynecological Oncology; ESTRO, European Society for Radiotherapy and Oncology; OTT, overall treatment time; RT, radiation therapy; SCC, squamous cell carcinoma. Additional considerations:		
• RetromBRACE study indicates a 0.5% to 1% increase in local control per day that the OTT is shortened. • ESGO Guidelines for vulvar cancer recommend completing RT within 8 weeks for optimal outcomes.		

Psychology

- B** Oncopsychologists should be included in the multidisciplinary team of caregivers for pregnant cancer patients.
- B** Psychological assessment and regular screening should be offered to these patients and their family during also beyond pregnancy using validated screening tools.
- B** Psychological support should be offered at every stage of the treatment process during and beyond pregnancy, not only for the patient but also for their partners, family and other supportive persons using evidence-based therapies.

Patient perspectives

- A** Patients and their partners should be informed, involved, and supported to make a shared decision regarding treatment and supportive care.
- A** Patients should be offered the possibility to receive peer support via available patient organizations.
- B** Rehabilitation programs should be offered to pregnant patients, similar to non-pregnant patients (as outpatient programs).
- A** Patients should be given the possibility to receive proper individualized support after treatment tailored to potential treatment side-effects (including lymphoedema), as well as guidance on sexuality, financial concerns, spirituality, nutrition, and returning to work.
- A** It is recommended to increase awareness to promote early diagnosis of cancer in pregnancy among patients and physicians.

Pediatric follow-up

Long-term toxicity monitoring programs are recommended for children exposed to cancer treatment in utero based on the specific treatment and its associated risks:

- B** • Hearing function should be monitored during childhood in children prenatally exposed to platinum-based chemotherapy (especially cisplatin).
- C** • Children exposed to anthracyclines in utero may be monitored for cardiotoxicity.
- B** • Clinical pediatric and neurodevelopmental vigilance is recommended for potential long-term toxicities (including secondary malignancies, fertility disorders, and other late effects due to the lack of long-term follow-up data).

Access the full ESGO Guidelines



© 2026 European Society of Gynaecological Oncology

All rights reserved. No part of this book can be reprinted, reproduced, transmitted or utilised in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or any information storage or retrieval system, without written permissions of ESGO. Reasonable efforts have been made to publish reliable data and information, but the authors and publisher cannot assume responsibility for the validity of all materials or for the consequences of their use, and the ultimate responsibility rests with the prescribing physician.

**European Society
of Gynaecological Oncology**

Avenue Emmanuel Mounier, 83/11
1200 Brussels, Belgium

adminoffice@esgomail.org
www.esgo.org

**© 2026 European Society
of Gynaecological Oncology.**
All rights reserved.